Challenges in Development of Nanomedicine for Treatment of Cancer


  • Dimple Sethi Chopra Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, India



Nanomaterials, Smart Cancer Nanomedicine, tumors, heterogeneity, overall survival, immunotherapeutics.


The inherent limitations of conventional cancer therapies have stimulated the growth of cancer nanomedicine. This is primarily attributable to its unique features for drug delivery, diagnosis and imaging, synthetic vaccine development and miniature medical devices, supplemented with the inherent therapeutic property of some nanomaterials. Nanotherapies that integrate some of these features are already in use and others have great potential in clinical development, with definitive results in near future. In order to develop smart cancer nanomedicine, it is very essential to bridge the gap between Bio-Nanoscience and Cancer Nanomedicine with a better understanding about the molecular basis of cancer. The development of smart cancer nanomedicine can be accelerated by patient stratification, rational drug selection, combination therapy, synergism with immunotherapeutics. The nanoplatforms that exhibit a significant increase in progression free survival are most desirable.


van der Meel R, Sulheim E, Shi Y. et al. Smart cancer nanomedicine. Nat Nanotechnol 2019; 14: 1007-1017. DOI:

Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017; 17: 20-37. DOI:

Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, Coussens LM, Daldrup-Link HE. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016; 11: 986-994. DOI:

Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160: 117-134. DOI:

Petersen GH, Alzghari SK, Chee W, Sankari SS, La-Beck NM. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional nonliposomal doxorubicin. J Control Release 2016; 232: 255-264. DOI:

Rugo HS, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab¬paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 33: 2361-2369. DOI:

Kato K, et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 2012; 30: 1621-1627. DOI:

Ahn HK, et al. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2014; 74: 277- 282. DOI:

Clark AJ, et al. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci USA 2016; 113: 3850-3854. DOI:

Ashton S, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med 2016; 8: 325ra17. DOI:

Hirsch LR, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003; 100: 13549-13554. DOI:

Maier-Hauff K, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011; 103: 317-324. DOI:

Maggiorella L, et al. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol 2012; 8: 1167-1181. DOI:

Dritschilo A, et al. Phase I study of liposome-encapsulated craf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006; 12: 1251-1259. DOI:

Elazar V, et al. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer 2010; 126: 1749-1760. DOI:

Davis ME, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070. DOI:

Yildiz I, Shukla S, Steinmetz NF. Applications of viral nanoparticles in medicine. Curr Opin Biotechnol 2011; 22: 901-908. DOI:

Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 2012; 20: 1831-1832. DOI:

Naldini L. Gene therapy returns to centre stage. Nature 2015; 351-360. DOI:

Shukla S, DiFranco NA, Wen AM, Commandeur U, Steinmetz NF. To target or not to target: active versus passive tumor homing of filamentous nanoparticles based on potato virus X. Cell Mol Bioeng 2015; 8: 433-444. DOI:

Czapar AE, et al. Tobacco mosaic virus delivery of phenanthriplatin for cancer therapy. ACS Nano 2016; 10: 4119-4126. DOI:

Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 2015; 219: 396-405. DOI:

Chow EK, et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 2011; 3: 73ra21. DOI:

Van der Meel R, Lammers T, Hennink WE. Cancer nanomedicines: oversold or underappreciated? Expert Opin Drug Deliv 2017; 14: 1-5. DOI:

Garbuzenko OB, et al. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010; 107: 10737-10742. DOI:

Kreiter S, et al. Mutant MHC class II epitopes drive therapeu-tic immune responses to cancer. Nature 2015; 520: 692-696. DOI:

Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534: 396-401. DOI:

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018; 17: 261-279. DOI:

Oberli MA, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett 2017; 17: 1326¬1335. DOI:

Sahin U, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547: 222-226. DOI:

Nel AE, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009; 8: 543-557. DOI:

Mahmoudi M, et al. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev 2011; 111: 5610¬5637. DOI:

Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66: 2-25. DOI:

Hrkach J, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012; 4: 128ra39. Firstin-human testing of a targeted, controlled-release polymeric NP for cancer chemotherapy. DOI:

Eliasof S, et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 2013; 110: 15127-15132. DOI:

Zuckerman JE, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA 2014; 111: 11449-11454. DOI:

Ritz S, et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 2015; 16: 1311-1321. DOI:

Björnmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Bridging Bio-Nano Science and Cancer Nanomedicine. ACS Nano 2017; 11(10): 9594-9613. DOI:

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.

Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 2015; 91: 3-6. DOI:

Kearney CJ, Mooney DJ. Macroscale delivery systems for molecular and cellular payloads. Nat Mater 2013; 12: 1004¬1017. DOI:

Lammers T, Kiessling F, Ashford M, Hennink W, Crommelin D, Storm G. Cancer nanomedicine: is targeting our target? Nat Rev Mater 2016; 1: 16069. DOI:

Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WC. Analysis of nanoparticle delivery to tumours. Nat Rev Mater 2016; 1: 16014. DOI:

Wang C, Ye Y, Hu Q, Bellotti A, Gu Z. Tailoring biomaterials for cancer immunotherapy: Emerging trends and future outlook. Adv Mater 2017; 29: 1606036. DOI:

Jiang W, Von Roemeling CA, Chen Y, Qie Y, Liu X, Chen J, Kim BY. Designing nanomedicine for immuno-oncology. Nat Biomed Eng 2017; 1: 0029. DOI:

Sun Q, Barz M, De Geest BG, Diken M, Hennink WE, Kiessling F, Lammers T, Shi Y. Nanomedicine and macroscale materials in immuno-oncology. Chem Soc Rev 2019; 48: 351-381. DOI:

Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev 2015; 115: 11109-11146. DOI:




How to Cite

Dimple Sethi Chopra. (2019). Challenges in Development of Nanomedicine for Treatment of Cancer . Journal of Cancer Research Updates, 8(1), 64–69.